Provirus load in patients with human T-cell leukemia virus type 1 uveitis correlates with precedent Graves' disease and disease activities
- PMID: 9703358
- PMCID: PMC5921870
- DOI: 10.1111/j.1349-7006.1998.tb03262.x
Provirus load in patients with human T-cell leukemia virus type 1 uveitis correlates with precedent Graves' disease and disease activities
Abstract
We previously demonstrated the increased provirus load in the peripheral blood of patients with human T-cell leukemia virus type 1 (HTLV-1) uveitis (HU). To delineate the relevance of the increased provirus load to clinical and immunologic parameters, we studied the correlation between them. Seventy-nine HU patients (24 male and 55 female) were included in the study, with their informed consent. Plasma samples and genomic DNA of the peripheral blood mononuclear cells were isolated and the provirus load was estimated by semi-quantitative polymerase chain reaction of the gag region sequence. Serum levels of anti-HTLV-1 antibodies and soluble IL-2R were determined by electrochemiluminescence immuno assay and by ELISA, respectively. Disease activities were assessed and graded 0 to 4 according to the evaluation system. Recurrence of the disease during the follow-up period was diagnosed ophthalmologically. The provirus load was significantly higher in the HU patients after Graves' disease (GD) than in those without GD (P<0.05). It correlated with disease activities assessed in terms of vitreous inflammation and interval to recurrence (both P<0.05). In the HU patients without GD, it correlated with the serum levels of soluble IL-2 receptor (P<0.01), and nearly with those of HTLV-1 antibody (P=0.063). These correlations were not found in the HU patients after GD under methimazole treatment. The results suggested a direct involvement of HTLV-1-infected cells in the pathogenesis of uveitis, and raise the possibility that hyperthyroidism may contribute to the clonal expansion of HTLV-1-infected cells.
Similar articles
-
Immunologic and virologic characterization of the primary infiltrating cells in the aqueous humor of human T-cell leukemia virus type-1 uveitis. Accumulation of the human T-cell leukemia virus type-1-infected cells and constitutive expression of viral and interleukin-6 messenger ribonucleic acids.Invest Ophthalmol Vis Sci. 1997 Mar;38(3):676-89. Invest Ophthalmol Vis Sci. 1997. PMID: 9071222
-
Human T-lymphotropic virus type I-associated uveitis in patients with Graves' disease treated with methylmercaptoimidazole.J Clin Endocrinol Metab. 1995 Jun;80(6):1904-7. doi: 10.1210/jcem.80.6.7775639. J Clin Endocrinol Metab. 1995. PMID: 7775639
-
An HTLV-I carrier with Graves' disease followed by uveitis: isolation of HTLV-I from thyroid tissue.Int J Hematol. 1997 Aug;66(2):233-7. doi: 10.1016/s0925-5710(97)00595-1. Int J Hematol. 1997. PMID: 9277055
-
Updates on HTLV-1 Uveitis.Viruses. 2022 Apr 12;14(4):794. doi: 10.3390/v14040794. Viruses. 2022. PMID: 35458524 Free PMC article. Review.
-
Human T-cell Leukemia Virus Type 1 (HTLV-1)-induced Uveitis.Ocul Immunol Inflamm. 2023 Sep;31(7):1416-1424. doi: 10.1080/09273948.2023.2175697. Epub 2023 Feb 21. Ocul Immunol Inflamm. 2023. PMID: 36803501 Review.
Cited by
-
Role of Viral Infections in the Pathogenesis of Sjögren's Syndrome: Different Characteristics of Epstein-Barr Virus and HTLV-1.J Clin Med. 2020 May 13;9(5):1459. doi: 10.3390/jcm9051459. J Clin Med. 2020. PMID: 32414149 Free PMC article. Review.
-
Identification of dysregulated pathways underlying HTLV-1-associated myelopathy/tropical spastic paraparesis through co-expression network analysis.J Neurovirol. 2021 Dec;27(6):820-830. doi: 10.1007/s13365-020-00919-z. Epub 2021 Jan 6. J Neurovirol. 2021. PMID: 33405203
-
Long-term follow-up of HTLV-1 proviral load in asymptomatic carriers and in incident cases of HAM/TSP: what is its relevance as a prognostic marker for neurologic disease?J Neurovirol. 2017 Feb;23(1):125-133. doi: 10.1007/s13365-016-0484-x. Epub 2016 Sep 27. J Neurovirol. 2017. PMID: 27678093
-
HTLV-I proviral load correlates with progression of motor disability in HAM/TSP: analysis of 239 HAM/TSP patients including 64 patients followed up for 10 years.J Neurovirol. 2001 Jun;7(3):228-34. doi: 10.1080/13550280152403272. J Neurovirol. 2001. PMID: 11517397
-
Safety of intraocular anti-VEGF antibody treatment under in vitro HTLV-1 infection.Front Immunol. 2023 Jan 25;13:1089286. doi: 10.3389/fimmu.2022.1089286. eCollection 2022. Front Immunol. 2023. PMID: 36761168 Free PMC article.
References
-
- ) Mochizuki , M. , Watanabe , T. , Yamaguchi , K. , Tajima , K. , Yoshimura , K. , Nakashima , S. , Shirao , M. , Araki , S. , Miyata , N. and Mori , S.An uveitis associated with human T‐lymphotropic virus type‐1 (HTLV‐1): seroepidemiological, clinical and virological studies . J. Infect. Dis. , 166 , 943 – 944 ( 1992. ). - PubMed
-
- ) Yoshimura , K. , Mochizuki , M. , Araki , S. , Miyata , N. , Yamaguchi , K. , Tajima , K. and Watanabe , T.Clinical and immunologic features of human T‐cell lymphotropic virus type I uveitis . Am. J. Ophthalmol. , 116 , 156 – 163 ( 1993. ). - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources